Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins

  • A. G. Mosser
  • D. A. Shepard
  • R. R. Rueckert
Conference paper
Part of the Archives of Virology Supplementum book series (ARCHIVES SUPPL, volume 9)


The WIN drugs and similar hydrophobic compounds that insert into the capsid of picornaviruses have been shown to block viral uncoating. In some of the human rhinoviruses they also block attachment of virus to cells. Spontaneously occurring drug-resistant mutants of human rhinovirus 14 and poliovirus type 3 were selected for their ability to make plaques in the presence of the selecting drug. The HRV-14 mutants either prevented drug binding or allowed the virus to attach to cells in the presence of drug. About two thirds of the poliovirus mutants were dependent on the presence of drug for plaque formation. In single cycle growth curves, drug was not required for the formation of drug-dependent progeny virus. However, progeny virus grown without drug never accumulated outside of cells, thus making the formation of plaques impossible. This behavior was apparently caused by the extreme thermolability of these mutants. In the absence of drug, heating to 37°C rapidly converted them to non-infectious particles with a sedimentation coefficient of 135S.


Plaque Assay Wild Type Virus Progeny Virus Human Rhinovirus 135S Particle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hogle J, Chow M, Filman DJ (1985) Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229: 1358–1365PubMedCrossRefGoogle Scholar
  2. 2.
    Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht H-J, Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B, Vriend G (1985) Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317: 145–153PubMedCrossRefGoogle Scholar
  3. 3.
    Olson NH, Kolatkar PR, Oliveira MA, Cheng RH, Greve JM, McClelland A, Baker TS, Rossmann MG (1993) Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci USA 90: 507–511PubMedCrossRefGoogle Scholar
  4. 4.
    Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, Kamarck ME, McClelland A (1989) The major human rhinovirus receptor is ICAM-1. Cell 56: 839–847PubMedCrossRefGoogle Scholar
  5. 5.
    Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA (1989) A cell adhesion molecule, IACM-1, is the major surface receptor for rhinoviruses. Cell 56: 849–853PubMedCrossRefGoogle Scholar
  6. 6.
    Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM (1989) Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J 8: 1567–1579PubMedGoogle Scholar
  7. 7.
    Kim S, Smith TJ, Chapman MS, Rossmann MG, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA (1989) Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol 210: 91–111PubMedCrossRefGoogle Scholar
  8. 8.
    Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, Rossmann MG, McKinlay MA, Diana GD, Otto MJ (1986) The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233: 1286–1293PubMedCrossRefGoogle Scholar
  9. 9.
    Badger J, Minor I, Oliveira MJ, Smith TJ, Griffith JP, Guerin DMA, Krishnaswamy S, Luo M, Rossmann MG, McKinlay MA, Diana GD, Dutko FJ, Fancher M, Rueckert RR, Heinz BA (1988) Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci USA 85: 3304–3308PubMedCrossRefGoogle Scholar
  10. 10.
    McKinlay M (1985) WIN 51711, a new systematically active broad-spectrum antipicornavirus agent. J Antimicrob Chemother 16: 284–286PubMedCrossRefGoogle Scholar
  11. 11.
    Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA (1985) In vitro activity of WIN 51711: a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 27: 883–886PubMedGoogle Scholar
  12. 12.
    Caliguiri LA, McSharry JJ, Lawrence GW (1980) Effect of arildone on modifications of poliovirus in vitro. Virology 105: 86–93PubMedCrossRefGoogle Scholar
  13. 13.
    Fox MP, Otto MJ, McKinlay MA (1986) The prevention of rhinovirus and poliovirus uncoating by WIN 51711: a new antiviral drug. Antimicrob Agents Chemother 30: 110–116PubMedGoogle Scholar
  14. 14.
    Gruenberger M, Pevear D, Diana GD, Kuechler E, Blaas D (1991) Stabilization of human rhinovirus serotpye 2 against pH induced conformational change by antiviral compounds. J Gen Virol 72: 431–433PubMedCrossRefGoogle Scholar
  15. 15.
    McSharry JJ, Caliguiri LA, Eggers HJ (1979) Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology 97: 307–315PubMedCrossRefGoogle Scholar
  16. 16.
    Zeichhardt H, Otto MJ, McKinlay MA, Willingmann P, Habermehl K-O (1987) Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology 160: 281–285PubMedCrossRefGoogle Scholar
  17. 17.
    Heinz BA, Rueckert RR, Shepard DA, Dutko FJ, McKinlay MA, Fancher M, Rossmann MG, Badger J, Smith T (1989) Genetic and molecular analysis of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol 63: 2476–2485PubMedGoogle Scholar
  18. 18.
    Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ (1989) Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol 63: 2002–2007PubMedGoogle Scholar
  19. 19.
    Heinz BA, Shepard DA, Rueckert RR (1990) Escape mutant analysis of a drug-binding site can be used to map functions in the rhinovirus capsid. In: Laver G, Air G (eds) Use of X-ray crystallography in the design of antiviral agents. Academic Press, New York, pp 173–186Google Scholar
  20. 20.
    Shepard DA, Heinz BA, Rueckert RR (1993) WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J Virol 67: 2245–2254PubMedGoogle Scholar
  21. 21.
    Mosser AG, Rueckert RR (1993) WIN 51711-dependent mutants of type 3 poliovirus: evidence that virions decay after release from cells unless drug is present. J Virol 67: 1246–1254PubMedGoogle Scholar
  22. 22.
    DeSena J, Mandell B (1977) Studies on the in vitro uncoating of poliovirus. II. Characterization of the membrane-modified particle. Virology 78: 554–566Google Scholar
  23. 23.
    Fricks CE, Hogle JM (1990) Cell-induced conformational changes of poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 64: 1934–1945PubMedGoogle Scholar
  24. 24.
    Kaplan G, Freistadt MS, Racaniello VR (1990) Neutralization of poliovirus by cell receptors expressed in insect cells. J Virol 64: 4697–4702PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • A. G. Mosser
    • 1
  • D. A. Shepard
    • 1
  • R. R. Rueckert
    • 1
  1. 1.Institute for Molecular VirologyUniversity of WisconsinMadisonUSA

Personalised recommendations